Rohit Bose, MD, PhD

Assistant Professor of Anatomy and Urology

Education

Instructor, 2018 - Dept. of Medicine, Genitourinary Service, Memorial Sloan Kettering Cancer Center

Fellowship, 2016 - Advanced Oncology, Memorial Sloan Kettering Cancer Center

Fellowship, Medical Research Track, 2014 - Medical Oncology, Memorial Sloan Kettering Cancer Center

Residency, Medical Research Track, 2010 - Internal Medicine, Weill Cornell Medicine

MD/PhD, 2008 - Medicine & Molecular Genetics, University of Toronto

Biography

I'm a physician-scientist and practising medical oncologist whose focus is prostate cancer. I see prostate cancer patients, and our lab's research program focuses on tumor evolution. We have developed a novel immunocompetent therapy-screening platform based on continuous tumor evolution without incurring the challenges of chromosomal instability or carcinogens. We focus on constraining cells in more therapy-sensitive states, which is crucial for improving patient care.

Research Interests

September 15, 2023 - August 31, 2028 - Simulating Ancestrally Unbiased Tumor Evolution to Interrogate Drug Resistance , Principal Investigator . Sponsor: NIH Common Fund, Sponsor Award ID: DP2CA290244

September 19, 2023 - August 31, 2026 - Simulating Ancestrally Unbiased Tumor Evolution To Interrogate Drug Resistance , Principal Investigator . Sponsor: NIH, Sponsor Award ID: DP2CA290244

July 1, 2022 - June 30, 2026 - Interrogating tumor sub-clonality and shifting dependencies to reduce castration therapy , . Sponsor: American Cancer Society, Sponsor Award ID: RSG-22-021-01-CDP

June 20, 2023 - June 19, 2026 - Profiling and Eliminating Tumor Subclones Destined for Resistance , . Sponsor: DOD Prostate Cancer Program, Sponsor Award ID: P0563731

September 15, 2018 - August 31, 2023 - Investigating How a Balance of Negative and Positive ETS Factors Controls Prostate Oncogenesis , Principal Investigator . Sponsor: NIH, Sponsor Award ID: K08CA226348

Publications

Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.

Publication Year

2023

Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal R, Small EJ, Fong L, Chou J, Friedlander T, de Kouchkovsky I, Koshkin VS

Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer.

Publication Year

2023

Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou J, Friedlander T, Koshkin VS

Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.

Publication Year

2022

Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, de Kouchkovsky I, Borno HT, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Aggarwal RR, Feng FY, Hope TA, Small EJ

The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.

Publication Year

2022

Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, Fraser M, Chesner L, Perry MD, Moreno-Rodriguez T, Chen WS, Alumkal JJ, Chou J, Morgans AK, Beer TM, Thomas GV, Gleave M, Lloyd P, Phillips T, McCarthy E, Haffner MC, Zoubeidi A, Annala M, Reiter RE, Rettig MB, Witte ON, Fong L, Bose R, Huang FW, Luo J, Bjartell A, Lang JM, Mahajan NP, Lara PN, Evans CP, Tran PT, Posadas EM, He C, Cui XL, Huang J, Zwart W, Gilbert LA, Maher CA, Boutros PC, Chi KN, Ashworth A, Small EJ, He HH, Wyatt AW, Quigley DA, Feng FY

Prospective Clinical Genomic Profiling of Ewing Sarcoma: ERF and FGFR1 Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic Relevance.

Publication Year

2022

Ogura K, Elkrief A, Bowman AS, Koche RP, de Stanchina E, Benayed R, Mauguen A, Mattar MS, Khodos I, Meyers PA, Healey JH, Tap WD, Hameed M, Zehir A, Shukla N, Sawyers C, Bose R, Slotkin E, Ladanyi M

Print this page